1,433
Views
4
CrossRef citations to date
0
Altmetric
Review

Helicobacter pylori drug resistance: therapy changes and challenges

, , , & ORCID Icon
Pages 819-827 | Received 25 Apr 2018, Accepted 29 Jun 2018, Published online: 13 Jul 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Atul Kumar Singh, Santosh Maurya & Shashank Kumar. (2023) Repurposing FDA-approved anti-diabetic drug to target H. pylori peptidyl deformylase using computer-based drug discovery approach. Molecular Simulation 49:1, pages 124-132.
Read now
Yu Wang, Jiong Tang, Su Zhou, Tian-Tian Liang, Fang-Fang Wang & Hong Ning. (2022) Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens?. Infection and Drug Resistance 15, pages 3733-3749.
Read now
Eyal Klang, Shelly Soffer, Yiftach Barash, Eyal Shachar & Adi Lahat. (2022) Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications. Clinical and Experimental Gastroenterology 15, pages 51-58.
Read now
Héctor Jesús Maldonado-Garza, Elvira Garza-González, Paola Bocanegra-Ibarias & Samantha Flores-Treviño. (2021) Diagnostic syndromic multiplex approaches for gastrointestinal infections. Expert Review of Gastroenterology & Hepatology 15:7, pages 743-757.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.